Acute Infectious Conjunctivitis

Okogen is specializing in the development of a treatment which drastically accelerates recovery of viral or bacterial conjunctivitis.

There are approximately 10 million cases of infectious conjunctivitis annually in the US.

Of the 10 million cases, approximately 60% are viral and 40% are bacterial.

Clinical differential diagnosis is extremely challenging as the signs and symptoms of disease are virtually indistinguishable. Both etiologies result in moderate to severe inflammation of the conjunctiva, the mucous membrane that covers the front of the eye and lines the inside of the eyelids.

Corneal opacity occurs in 20-50% of viral conjunctivitis cases, and can lead to scarring or clouding of the cornea. Significantly, this may result in long-term visual impairment and premature/chronic dry eye.

Signs and symptoms of infectious conjunctivitis include eye pain, redness, swelling and discharge, which cause significant discomfort and embarrassment.

Currently it takes 2-3 weeks to resolve without treatment. OKG-0303 will significantly shorten the infection and associated symptoms.

OKG-0303 Fixed Dose Combination

OKG-0301
(Antiviral)

Ocular Antibiotic
(Antibacterial)

Alpha Adrenergic Receptor Agonist
(Sign & Symptom Relief)

Mechanism of Action(s)

Without Treatment

Virus causes conjunctivitis via replication in infected cells

With OKG-0301 Treatment

The anti-viral preferentially enters virally infected cells and inhibits viral replication

With OKG-0502 Treatment

The anti-viral inhibits viral replication and the ocular decongestant reduces redness & discharge

With OKG-0303 Treatment

The anti-viral inhibits viral replication and the ocular decongestant reduces redness & discharge